Piper Sandler & Co.

Piper Sandler & Co.

Piper Sandler & Co.


800 Nicollet Mall Minneapolis MN 55402

Type of Company



Retail & Commercial Banking

Company Description

Piper Jaffray is a full-service investment bank and asset management firm focused on mergers and acquisitions, financial restructuring, public offerings, public finance, institutional brokerage, investment management and securities research. Piper Jaffray traces its roots to 1895 when George Lane established George B. Lane, Commercial Paper and Collateral Loans & Co., a commercial paper brokerage, in Minneapolis. In 1913, Piper, Jaffray Co. was established as another commercial paper business by H.C. Piper Sr. and C.P. Jaffray. In 1917, George B. Lane & Co. merged with Piper, Jaffray & Co. to form Lane, Piper & Jaffray. The firm first obtained a seat on the New York Stock Exchange in 1931 with the acquisition of Hopwood & Company, which had been devastated by the stock market crash. In 1971, Piper first offered stock to the public and became a publicly held corporation known as Piper, Jaffray & Hopwood Incorporated. Later, in 1986, Piper's common stock began trading on the NASDAQ under the ticker symbol PIPR. In 1997, the firm was acquired by U.S. Bancorp, also based in Minneapolis, for $730 million in cash. From 1999 to 2003, the firm was known as U.S. Bancorp Piper Jaffray.

Executives & Employees

Chief Executive Officer

Secretary & General Counsel

Group Head, Healthcare Investment Banking

Head of TMT M&A

Co-Head, Diversified Industrials & Services Investment Banking

Managing Director, Global Co-Head of Investment Banking & Capital Markets

Co-Head, Diversified Industrials & Services Investment Banking

Head of Healthcare & Senior Living Finance Group Public Finance Investment Banking

Vice Chairman of Investment Banking

Managing Director

Paths to Piper Sandler & Co.
Potential Connections via
Relationship Science
Piper Sandler & Co.
Recent Transactions
Details Hidden

BigCommerce Holdings, Inc. issued USD Common Stock

Details Hidden

Accolade, Inc. issued USD Common Shares

Details Hidden

Praxis Precision Medicines, Inc. issued USD Common Stock

Transaction Clients
Selling Group Member

Advised on TD Waterhouse Group, Inc. issued USD Common Stock

Selling Group Member

Advised on The Goldman Sachs Group, Inc. issued USD Common Stock


Advised on Adverum Biotechnologies, Inc. issued USD Common Stock

Transaction Advisors
Legal Advisor

Advised onAlloVir, Inc. issued USD Common Stock

Legal Advisor

Advised onSea Ltd. (Singapore) issued USD American Depositary Shares

Legal Advisor

Advised onKeane Group, Inc. issued USD Common Stock

Legal Advisor

Advised onDeciphera Pharmaceuticals, Inc. issued USD Common Stock

Deputy Office Managing Partner

Advised onGardner Denver Holdings, Inc. issued USD Common Stock

Global Chair, Corporate Department

Advised onGardner Denver Holdings, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Latham & Watkins LLP

Legal Advisor

Partner at Foley Ventures LLC

Legal Advisor

Former Partner at Faegre Baker Daniels LLP


CoPERA’s trust funds are invested under the direction of a board of trustees. Their investment strategy uses actuarially established asset allocation investment objectives with long-term goals and policies. Assets are diversified into domestic and international stocks, corporate, government, and international bonds, mortgages, real estate and alternative investments. The fund is long-term in nature and the selection of investments is regulated by statutory limitation, investment time horizon, the limits of acceptable risk and the objective of optimizing the total rate of return. The targeted strategic asset allocation is designed to provide an optimal diversification to reduce risk and maximize total rate of return relative to risk. Many of CoPERA's actively managed portfolios are managed by outside sub-advisors.

Non-Profit Donations & Grants
$5,000 - $10K
$10K - $25K
Details Hidden

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Piper Sandler & Co.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Piper Sandler & Co.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Piper Sandler & Co..